XL-495

N/A

Report date: 2025/06/26 20:00:07
NME

Base Information

Drug NameXL-495
Drug Alias NameXL-495XL495
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase inhibitors
TargetsMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesExelixis Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Transitional Cell

Other Information

ATC CodeN/A
Related LinksN/A